Popular Articles
Teeth Whitening Products

ONGLYZA™ (Saxagliptin) Receives Positive Opinion In Europe For The Treatment Of Type 2 Diabetes
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced that their marketing authorization application for ONGLYZA™ (saxagliptin) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea.
generic viagra online
Raptor Pharmaceuticals Doses First Patient In Phase 2b Clinical Trial Of DR Cysteamine For Cystinosis
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor"s proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease. Under Raptor"s open Investigational New Drug application ("IND"), UCSD is performing the Raptor-sponsored trial at its General Clinical Research Center.
News of the day
Cook Medical And LMA Urology Ltd Forge Global Partnership To Advance Global Treatment Of Stone Disease
Cook Medical and LMA Urology Ltd have entered into a strategic partnership that can significantly improve the remedies available for stone disease management. Through the worldwide agreement, Cook will market and distribute LMA"s StoneBreakerTM, a portable pneumatic lithotripter for stone fragmentation.
Public Health

Drug-Free Flipping Of The Brain's Addiction Switch

When someone becomes dependent on drugs or alcohol, the brain"s pleasure center gets hijacked, disrupting the normal functioning of its reward circuitry. Researchers investigating this addiction "switch" have now implicated a naturally occurring protein, a dose of which allowed them to get rats hooked with no drugs at all. The research will be published Friday in the journal Science. "If we can understand how the brain"s circuitry changes in association with drug abuse, it could potentially suggest ways to medically counteract the effects of dependency," said Scott Steffensen, a neuroscientist at Brigham Young University who co-authored the study with two of his undergraduate students, one of his grad students, and a team of researchers at the University of Toronto. Chronic drug users, as noted by previous research, can experience an increase of a naturally-occurring protein called BDNF (brain-derived neurotrophic factor) in the brain"s reward circuitry, a region scientists call the ventral tegmental area. In this study, the researchers took the drugs out of the equation and directly infused extra BDNF onto this part of the brain in rats. The Toronto team noted that a single injection of BDNF made rats behave as though they were dependent on opiates (which they had never received). Though rats instinctively prefer certain smells, lighting and texture, these rats left their comfort zone in search of a fix. "This work may reveal a mechanism that underlies drug addiction," said lead author Hector Vargas-Perez, a neurobiologist at the University of Toronto. The BYU team confirmed that the protein is a critical regulator of drug dependency. After the BDNF injection, specific chemicals that normally inhibit neurons in this part of the brain instead excited them, a "switch" known to occur when people become dependent on drugs. Steffensen, who teaches in BYU"s psychology department, says this work suggests that BDNF is crucial for inducing a drug dependent state, one important aspect of drug addiction. BYU undergrad and study co-author Micah Hansen researched in Steffensen"s neuroscience lab from his freshman year through his graduation one month ago. Fellow BYU undergrad Christine Walton, also a coauthor, completed her degree a year earlier and now works as an addiction researcher at the National Institutes of Health in Bethesda, Md. David Allison, a psychology graduate student at BYU, is also a co-author. Joe Hadfield Brigham Young University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):